On July 17, 2020, Fairhaven Pharmaceuticals announced that it has been acquired by Liminal BioSciences. The acquisition includes Fairhaven’s preclinical research program of small molecule antagonists. Investigational therapies developed in the R&D program target a key chemoattractant and activator of eosinophils, which play a key role in inflammation-driven diseases.The acquisition continues Liminal’s strategic expansion to create a diverse portfolio of early stage R&D programs that complement its existing research.
Fairhaven Pharmaceuticals specializes in the development of small molecule, oral therapeutics for severe inflammatory conditions.
Liminal BioSciences is a clinical stage biopharmaceutical company specializing in discovering, developing and commercializing treatments for patients suffering from diseases related to fibrosis.
Osler, Hoskin & Harcourt LLP advised Fairhaven with a team consisting of David Jamieson, Kosta Starostin (Corporate), Martha Martindale (Financial Services), Colena Der (Taxation) and Amelia Miao (Securities).